Paris, France - January 7, 2013, Paris, France - Sanofi, a pharmaceutical company, announced the appointment of Gary J. Nabel as chairman of the Strategic Development and Scientific Advisory Council (SDSAC).
Article continues below
Mr. Nabel joined Sanofi from the National Institutes of Health, where he served as Director of the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases since 1999.
During his tenure at the NIH, he provided scientific leadership of the basic, clinical, and translational research activities of the VRC and guides development of novel vaccine strategies against HIV, Ebola/Marburg hemorrhagic fevers, influenza, chikungunya and other viruses.
Mr. Nabel has an extensive and distinguished background of academic and hospital appointments, and committee memberships including numerous prestigious awards and honors and an extensive publication record.
He graduated magna cum laude from Harvard College in 1975 and continued his graduate studies at Harvard University, completing his Ph.D. in 1980 and his M.D. in 1982.
Mr. Nabel served as a postdoctoral fellow in the laboratory of David Baltimore at MIT’s Whitehead Institute. Before his appointment at the Vaccine Research Center, he served as the Henry Sewall Professor of Internal Medicine, Professor of Biochemistry, and Howard Hughes Medical Institute Investigator at the University of Michigan in Ann Arbor.
In addition to his faculty positions, Mr. Nabel also served as the Director of the Center for Gene Therapy and co-director of the Center for Molecular Medicine at the University of Michigan.
In recognition of his expertise at the forefront of virology, immunology, gene therapy, and molecular biology, he was elected as a member of the Institute of Medicine of the National Academy of Sciences in 1998.
Mr. Nabel, currently Senior Vice President, Chief Scientific Officer and Deputy to President of Global R&D, will succeed Richard Klausner.
Mr. Klausner is the former Executive Director for Global Health of the Bill and Melinda Gates Foundation. He was Director of the National Cancer Institute (NCI) between 1995 and 2001. He is currently partner at the Column Group, a San Francisco based venture firm.
His research has been recognized with awards including the Outstanding Investigator Award from the American Federation of Clinical Research and the William Damashek Prize for major discoveries in haematology.
Mr. Klausner received the 1997-1998 Dickson Prize in Medicine and the 1998 Raymond Bourgine Award. He has served as an Advisor to the Presidents of the Academies on counterterrorism and as Liaison to the White House Office of Science & Technology Policy.
He is a member of the National Academy of Sciences, the Institute of Medicine and the American Academy of Arts and Sciences. ■